Tailored immunosuppression after kidney transplantation - a single center real-life experience
- PDF / 1,118,297 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 36 Downloads / 171 Views
RESEARCH ARTICLE
Open Access
Tailored immunosuppression after kidney transplantation - a single center real-life experience Miriam Good-Weber1, Malgorzata Roos2, Thomas F. Mueller1, Barbara Rüsi3 and Thomas Fehr1,4*
Abstract Background: Kidney allograft survival continuously improved with introduction of novel immunosuppressants. However, also immunologically challenging transplants (blood group incompatibility and sensitized recipients) increase. Between 2006 and 2008, a new tailored immunosuppression scheme for kidney transplantation was implemented at the University Hospital in Zurich, together with an ABO-incompatible transplant program and systematic pre- and posttransplant anti-human leukocyte antigen (HLA) antibody screening by Luminex technology. This study retrospectively evaluated the results of this tailored immunosuppression approach with a particular focus on immunologically higher risk transplants. Methods: A total of 204 consecutive kidney transplantations were analyzed, of whom 14 were ABO-incompatible and 35 recipients were donor-specific anti-HLA antibodies (DSA) positive, but complement-dependent cytotoxicity crossmatch (CDC-XM) negative. We analyzed patient and graft survival, acute rejection rates and infectious complications in ABO-compatible versus -incompatible and in DSA positive versus negative patients and compared those with a historical control group. Results: Overall patient, death-censored allograft survival and non-death-censored allograft survival at 4 years were 92, 91 and 87%, respectively. We found that (1) there were no differences between ABO-compatible and -incompatible and between DSA positive and DSA negative patients concerning acute rejection rate and graft survival; (2) compared with the historical control group there was a significant decrease of acute rejection rates in sensitized patients who received an induction with thymoglobulin; (3) there was no increased rate of infection among the patients who received induction with thymoglobulin compared to no induction therapy. Conclusions: We observed excellent overall mid-term patient and graft survival rates with our tailored immunosuppression approach. Induction with thymoglobulin was efficient and safe in keeping rejection rates low in DSA positive patients with a negative CDC-XM. Keywords: Kidney transplantation, Induction therapy, Thymoglobulin, Donor-specific antibodies, ABOincompatibility, Rejection
* Correspondence: [email protected] 1 Division of Nephrology, University Hospital Zurich, Zurich, Switzerland 4 Department of Internal Medicine, Cantonal Hospital Graubünden, Loestrasse 170, 7000 Chur, Switzerland Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons l
Data Loading...
